MKI67 and mantle cell lymphoma: For example, our analyses provides the first population‐based data on the cell proliferation marker Ki67, revealing that around two‐thirds of MCL patients initially fall into the <30% category, and confirming its prognostic role alone, as well as in combination with the MIPI score (Figure S5) (Klapper et al, 2009; Hoster et al, 2016).